---
title: "Lysergide (DT120) in Generalized anxiety disorder: Administration"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Administration. Topics: Orally disintegrating tablet, Required 8-hour monitoring and end-of-session checklist in the Phase 3 trials, End-of-session checklist content and development, Session length in Voyage: topline announcement, and 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/administration"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Orally disintegrating tablet

> “Zydis ODT is a unique, freeze-dried, oral solid dosage form that disperses almost instantly in the mouth, without the need for water.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “DT120 ODT disintegrates in seconds”
> “Normal activities resume the next day, including driving”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.10.2-2"></a>

### Required 8-hour monitoring and end-of-session checklist in the Phase 3 trials

> “Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”
> “Dosing and monitoring paradigm based on Phase 3 clinical protocols.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “Participants were monitored for a minimum of 8 hours on dosing day and were assessed hourly beginning 5 hours after dosing on a structured end-of-session checklist (EoSC).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The EoSC is an 8-question checklist used to assess participant readiness for completion of monitoring after receiving DT120.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.1.2.10.2-3"></a>

### End-of-session checklist content and development

> “Predetermined safety criteria were used to assess readiness to end the dosing session, such as orientation to person, place, and time; resolution of cognitive, perceptual, and emotional effects; and no evidence of suicidal ideation”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

> “12-hour monitoring requirement based on inclusion of 200 μg dose of DT120 in Phase 2b”
> “The required monitoring period in pivotal studies of DT120 is 8 hours and requires that participants clear the End of Session Checklist.”
> “EOSC intended to inform & reflect requirements under potential REMS program”
> “Refined based on discussions with the FDA”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.1.2.10.2-4"></a>

### Session length in Voyage: topline announcement

> “On the day of dosing, participants were assessed hourly beginning at hour 5 post-dose on a structured end-of-session checklist (EoSC).”
> “The average time to meeting EoSC criteria was 6.4 hours for participants receiving DT120 ODT in Part A, with a median of 6.1 hours and 92% of participants meeting the EoSC criteria by hour 8.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.10.2-5"></a>

### Session length in Voyage: congress poster

> “Average time to End-of-Session Checklist (EoSC) clearance was 6.4 hours (Figure 6).”
> “More than half of participants met all EoSC criteria at hour 6, and the majority of participants (90%) met all EoSC criteria by hour 8”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.1.2.10.2-6"></a>

### Session length in Panorama and across the Phase 3 trials

> “The average time to meet EoSC criteria was 6.2 hours for participants receiving DT120 ODT 100 μg, with a median of 6.0 hours and 94% of participants meeting EoSC criteria by hour 8.”
> “Across over 1,000 treatment sessions in the Phase 3 program through September 10, 2026, 97% of participants met EoSC criteria by hour 8.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Consistent average time to clearance of EoSC of ~6 hours across studies”
> “Two thirds of participants clear EoSC at hour 6”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.10.2-7"></a>

### Dosing session monitors and on-call clinician in the Phase 3 trials

> “Two qualified and trained DSMs monitored dosing, with the second DSM having the option to monitor remotely via video.”
> “A total of 3 DSMs were onsite, and a licensed HCP was available or on call ≤15 minutes from the site”
> “Standardized EoSC was used to assess participant status and ability to end the dosing session”
> “Site raters could not serve as the DSM or HCP for the same participant after the screening or baseline assessments to mitigate functional unblinding”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “In a clinical trial, an LSD dosing session is conducted in a comfortable, supportive environment with medical professionals called Dosing Session Monitors (DSMs) who passively observe and assist participants.”
> “A healthcare provider is on call to provide medical oversight.”

Source: [Definium Therapeutics LSD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/08/DFTX-FactSheet-LSD-080526.pdf)

<a id="topic-2.1.2.10.2-8"></a>

### Phase 2b dosing session procedures and 12-hour monitoring

> “On the dosing day, participants received a single oral dose of MM120 or placebo.”
> “Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.”
> “Participant dosing sessions were conducted individually in a private aesthetically pleasant room.”
> “Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.”
> “Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.”
> “Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects.”
> “Continuous monitoring was required for a minimum of 12 hours.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.10.2-9"></a>

### Phase 2b: time to meet criteria to end the session at 100 µg

> “In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours.”
> “All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.10.2-10"></a>

### Regulatory expectations for monitoring a psychedelic treatment session

> “Subjects receiving active treatment with psychedelic drugs may remain in a vulnerable state for several hours or longer.”
> “Observation by two monitors for the duration of the treatment session.”
> “If the lead monitor is not a physician, availability of a licensed on-call physician able to reach the clinical site within 15 minutes in the event of a medical emergency.”
> “Sponsors should plan to provide a quantitative and qualitative assessment of the drug effects, including effects on orientation to time and place, thought and perception, and subjective effects across time that could inform recommendations for monitoring, safety of discharge, and impact on driving.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
